[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUjf6DqMBE1OVasGrFwIZKGP8Jp22V_QntFws6rVZSCQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":52,"rows":59},"University of Cape Town",[4],115,false,14,15,155962,6,78,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Tuberculosis",20,{"name":18,"count":19},"HIV",9,{"name":21,"count":11},"HIV Infections",{"name":23,"count":24},"Malaria",5,{"name":26,"count":27},"Hiv",4,{"name":29,"count":30},"Obesity",3,{"name":32,"count":33},"COVID-19",2,{"name":35,"count":33},"Tuberculous Pericarditis",[37,42,47],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04521803","High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis","2025-09-15","high dose Rifampicin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04147286","Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion","2025-09-30","Atorvastatin 40mg",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04951986","Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","2025-12-15","Rifampin",[53,54,55,56,57,58],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[60,109,138,161,179,197,235,270,288,313,339,366,384,410,428,446,468,493,522,548,566,584,602,620,638,656,681,705,731,749,774,802,820,846,864,899,925,943,961,979,1005,1023,1041,1067,1092,1110,1146,1187,1213,1241,1259,1277,1305,1330,1348,1373,1399,1417],{"intervention":61,"totalTrials":33,"cells":62},"Levofloxacin",{"EARLY_PHASE1":63,"PHASE1":66,"PHASE2":68,"PHASE3":70,"PHASE4":105,"NA":107},{"trials":64,"activeCount":65},[],0,{"trials":67,"activeCount":65},[],{"trials":69,"activeCount":65},[],{"trials":71,"activeCount":104,"soonestReadout":50},[72,93],{"nctId":73,"briefTitle":74,"status":75,"phases":76,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":84},"NCT02454205","An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","COMPLETED",[55,56],"2020-12-31","2021-08-30","2015-11-12",154,[15,82,83],"Multidrug Resistant Tuberculosis","Extensively-drug Resistant Tuberculosis",[85,86,61,87,88,89,90,91,92],"Linezolid","Bedaquiline","Pyrazinamide","Isoniazid","Ethionamide","Terizidone","Moxifloxacin","Kanamycin",{"nctId":48,"briefTitle":49,"status":94,"phases":95,"primaryCompletion":50,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"ACTIVE_NOT_RECRUITING",[56],"2026-03","2021-08-11",732,[100,18],"Disseminated Tuberculosis",[51,61,102,103],"Rifampicin, Pyrazinamide, Ethambutol and Isoniazid","Prednisone",1,{"trials":106,"activeCount":65},[],{"trials":108,"activeCount":65},[],{"intervention":103,"totalTrials":33,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":134,"NA":136},{"trials":112,"activeCount":65},[],{"trials":114,"activeCount":65},[],{"trials":116,"activeCount":65},[],{"trials":118,"activeCount":104,"soonestReadout":50},[119,130],{"nctId":120,"briefTitle":121,"status":75,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT01924286","Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone",[56],"2016-04","2017-04","2013-08-30",240,[128,18,15],"Immune Reconstitution Inflammatory Syndrome",[103],{"nctId":48,"briefTitle":49,"status":94,"phases":131,"primaryCompletion":50,"completion":96,"start":97,"enrollment":98,"conditions":132,"interventions":133},[56],[100,18],[51,61,102,103],{"trials":135,"activeCount":65},[],{"trials":137,"activeCount":65},[],{"intervention":46,"totalTrials":104,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":157,"NA":159},{"trials":141,"activeCount":65},[],{"trials":143,"activeCount":65},[],{"trials":145,"activeCount":65},[],{"trials":147,"activeCount":104,"soonestReadout":45},[148],{"nctId":43,"briefTitle":44,"status":149,"phases":150,"primaryCompletion":45,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"RECRUITING",[55,56],"2027-09-30","2020-07-14",220,[155],"Tuberculosis, Pulmonary",[46],{"trials":158,"activeCount":65},[],{"trials":160,"activeCount":65},[],{"intervention":51,"totalTrials":104,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":175,"NA":177},{"trials":164,"activeCount":65},[],{"trials":166,"activeCount":65},[],{"trials":168,"activeCount":65},[],{"trials":170,"activeCount":104,"soonestReadout":50},[171],{"nctId":48,"briefTitle":49,"status":94,"phases":172,"primaryCompletion":50,"completion":96,"start":97,"enrollment":98,"conditions":173,"interventions":174},[56],[100,18],[51,61,102,103],{"trials":176,"activeCount":65},[],{"trials":178,"activeCount":65},[],{"intervention":102,"totalTrials":104,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":193,"NA":195},{"trials":182,"activeCount":65},[],{"trials":184,"activeCount":65},[],{"trials":186,"activeCount":65},[],{"trials":188,"activeCount":104,"soonestReadout":50},[189],{"nctId":48,"briefTitle":49,"status":94,"phases":190,"primaryCompletion":50,"completion":96,"start":97,"enrollment":98,"conditions":191,"interventions":192},[56],[100,18],[51,61,102,103],{"trials":194,"activeCount":65},[],{"trials":196,"activeCount":65},[],{"intervention":41,"totalTrials":33,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":200,"activeCount":65},[],{"trials":202,"activeCount":65},[],{"trials":204,"activeCount":104,"soonestReadout":40},[205,213],{"nctId":38,"briefTitle":39,"status":149,"phases":206,"primaryCompletion":40,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},[55],"2026-02-28","2022-01-10",60,[35,211],"HIV Status",[41],{"nctId":214,"briefTitle":215,"status":75,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":224},"NCT03927313","Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM",[55],"2021-03-30","2021-03-31","2019-06-12",52,[222,223],"Tuberculosis Meningitis","HIV-1-infection",[85,225,226,227,228],"High dose rifampicin","Aspirin","Standard of Care anti-tuberculous therapy","Dexamethasone",{"trials":230,"activeCount":65},[],{"trials":232,"activeCount":65},[],{"trials":234,"activeCount":65},[],{"intervention":236,"totalTrials":33,"cells":237},"Artemether\u002FLumefantrine",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":268},{"trials":239,"activeCount":65},[],{"trials":241,"activeCount":65},[],{"trials":243,"activeCount":65},[],{"trials":245,"activeCount":65},[],{"trials":247,"activeCount":65},[248,259],{"nctId":249,"briefTitle":250,"status":75,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":257},"NCT00790881","Artemether\u002FLumefantrine and Nevirapine Interaction Study in HIV-infected Adults",[57],"2009-08","2009-12","2008-10",36,[23,18],[236,258],"Artemether\u002F lumefantrine",{"nctId":260,"briefTitle":261,"status":75,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":267},"NCT00869700","Pharmacokinetic Interaction Between the Antimalarial Combination Artemether\u002FLumefantrine and Combination Antiretroviral Therapy Including Lopinavir\u002FRitonavir in HIV-infected Adults",[57],"2010-02","2009-06",18,[21,23],[236],{"trials":269,"activeCount":65},[],{"intervention":258,"totalTrials":104,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":65},[],{"trials":275,"activeCount":65},[],{"trials":277,"activeCount":65},[],{"trials":279,"activeCount":65},[],{"trials":281,"activeCount":65},[282],{"nctId":249,"briefTitle":250,"status":75,"phases":283,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":284,"interventions":285},[57],[23,18],[236,258],{"trials":287,"activeCount":65},[],{"intervention":289,"totalTrials":104,"cells":290},"Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":311},{"trials":292,"activeCount":65},[],{"trials":294,"activeCount":65},[],{"trials":296,"activeCount":65},[],{"trials":298,"activeCount":65},[],{"trials":300,"activeCount":65},[301],{"nctId":302,"briefTitle":303,"status":304,"phases":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":310},"NCT00242047","Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.","UNKNOWN",[57],"2006-08","2001-03",12000,[15],[289],{"trials":312,"activeCount":65},[],{"intervention":314,"totalTrials":104,"cells":315},"Methoxyflurane",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":337},{"trials":317,"activeCount":65},[],{"trials":319,"activeCount":65},[],{"trials":321,"activeCount":65},[],{"trials":323,"activeCount":65},[],{"trials":325,"activeCount":65},[326],{"nctId":327,"briefTitle":328,"status":304,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT03849027","MethOxyflUraNe at moderaTe High AltItudes for PAIN Management",[57],"2019-09","2019-12","2019-05",24,[335],"Pain",[314],{"trials":338,"activeCount":65},[],{"intervention":340,"totalTrials":104,"cells":341},"Diclofenac 50 mg tds",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":364},{"trials":343,"activeCount":65},[],{"trials":345,"activeCount":65},[],{"trials":347,"activeCount":65},[],{"trials":349,"activeCount":65},[],{"trials":351,"activeCount":65},[352],{"nctId":353,"briefTitle":354,"status":355,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":65,"conditions":360,"interventions":362},"NCT00954785","Etoricoxib in Acute Ankle Ligament Sprains","WITHDRAWN",[57],"2010-12","2011-07","2009-11",[361],"Sprain",[340,363],"Etoricoxib 120 mg mane",{"trials":365,"activeCount":65},[],{"intervention":363,"totalTrials":104,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":382},{"trials":369,"activeCount":65},[],{"trials":371,"activeCount":65},[],{"trials":373,"activeCount":65},[],{"trials":375,"activeCount":65},[],{"trials":377,"activeCount":65},[378],{"nctId":353,"briefTitle":354,"status":355,"phases":379,"primaryCompletion":357,"completion":358,"start":359,"enrollment":65,"conditions":380,"interventions":381},[57],[361],[340,363],{"trials":383,"activeCount":65},[],{"intervention":385,"totalTrials":104,"cells":386},"8 hourly LPV\u002Fr during TB treatment",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":408},{"trials":388,"activeCount":65},[],{"trials":390,"activeCount":65},[],{"trials":392,"activeCount":65},[],{"trials":394,"activeCount":65},[],{"trials":396,"activeCount":65},[397],{"nctId":398,"briefTitle":399,"status":75,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT01637558","Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)",[57],"2017-07-31","2012-11",200,[15,18],[385,406,407],"Nevirapine","Lopinavir\u002FRitonavir",{"trials":409,"activeCount":65},[],{"intervention":406,"totalTrials":104,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":426},{"trials":413,"activeCount":65},[],{"trials":415,"activeCount":65},[],{"trials":417,"activeCount":65},[],{"trials":419,"activeCount":65},[],{"trials":421,"activeCount":65},[422],{"nctId":398,"briefTitle":399,"status":75,"phases":423,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":424,"interventions":425},[57],[15,18],[385,406,407],{"trials":427,"activeCount":65},[],{"intervention":407,"totalTrials":104,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":444},{"trials":431,"activeCount":65},[],{"trials":433,"activeCount":65},[],{"trials":435,"activeCount":65},[],{"trials":437,"activeCount":65},[],{"trials":439,"activeCount":65},[440],{"nctId":398,"briefTitle":399,"status":75,"phases":441,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":442,"interventions":443},[57],[15,18],[385,406,407],{"trials":445,"activeCount":65},[],{"intervention":85,"totalTrials":33,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":458,"PHASE4":464,"NA":466},{"trials":449,"activeCount":65},[],{"trials":451,"activeCount":65},[],{"trials":453,"activeCount":65},[454],{"nctId":214,"briefTitle":215,"status":75,"phases":455,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":456,"interventions":457},[55],[222,223],[85,225,226,227,228],{"trials":459,"activeCount":65},[460],{"nctId":73,"briefTitle":74,"status":75,"phases":461,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":462,"interventions":463},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":465,"activeCount":65},[],{"trials":467,"activeCount":65},[],{"intervention":469,"totalTrials":104,"cells":470},"Cotrimoxazole",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":489,"NA":491},{"trials":472,"activeCount":65},[],{"trials":474,"activeCount":65},[],{"trials":476,"activeCount":65},[],{"trials":478,"activeCount":65},[479],{"nctId":480,"briefTitle":481,"status":75,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT00330304","Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children",[56],"2011-11-15","2003-01",450,[15],[88,469,488],"isoniazid",{"trials":490,"activeCount":65},[],{"trials":492,"activeCount":65},[],{"intervention":494,"totalTrials":104,"cells":495},"Chloral Hydrate",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":518,"NA":520},{"trials":497,"activeCount":65},[],{"trials":499,"activeCount":65},[],{"trials":501,"activeCount":65},[],{"trials":503,"activeCount":65},[504],{"nctId":505,"briefTitle":506,"status":75,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":517},"NCT02195661","The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children",[56],"2017-09","2017-10","2014-04",194,[513,514,515,516],"Epilepsy","Electroencephalogram","Children","Sedation",[494],{"trials":519,"activeCount":65},[],{"trials":521,"activeCount":65},[],{"intervention":523,"totalTrials":104,"cells":524},"Nitazoxanide",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":544,"NA":546},{"trials":526,"activeCount":65},[],{"trials":528,"activeCount":65},[],{"trials":530,"activeCount":65},[],{"trials":532,"activeCount":65},[533],{"nctId":534,"briefTitle":535,"status":536,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":543},"NCT04523090","Catalysing the Containment of COVID-19","TERMINATED",[55,56],"2021-12-21","2022-08-12","2020-08-27",322,[32],[523],{"trials":545,"activeCount":65},[],{"trials":547,"activeCount":65},[],{"intervention":86,"totalTrials":104,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":562,"NA":564},{"trials":551,"activeCount":65},[],{"trials":553,"activeCount":65},[],{"trials":555,"activeCount":65},[],{"trials":557,"activeCount":65},[558],{"nctId":73,"briefTitle":74,"status":75,"phases":559,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":560,"interventions":561},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":563,"activeCount":65},[],{"trials":565,"activeCount":65},[],{"intervention":87,"totalTrials":104,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":580,"NA":582},{"trials":569,"activeCount":65},[],{"trials":571,"activeCount":65},[],{"trials":573,"activeCount":65},[],{"trials":575,"activeCount":65},[576],{"nctId":73,"briefTitle":74,"status":75,"phases":577,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":578,"interventions":579},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":581,"activeCount":65},[],{"trials":583,"activeCount":65},[],{"intervention":89,"totalTrials":104,"cells":585},{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":598,"NA":600},{"trials":587,"activeCount":65},[],{"trials":589,"activeCount":65},[],{"trials":591,"activeCount":65},[],{"trials":593,"activeCount":65},[594],{"nctId":73,"briefTitle":74,"status":75,"phases":595,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":596,"interventions":597},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":599,"activeCount":65},[],{"trials":601,"activeCount":65},[],{"intervention":90,"totalTrials":104,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":616,"NA":618},{"trials":605,"activeCount":65},[],{"trials":607,"activeCount":65},[],{"trials":609,"activeCount":65},[],{"trials":611,"activeCount":65},[612],{"nctId":73,"briefTitle":74,"status":75,"phases":613,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":614,"interventions":615},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":617,"activeCount":65},[],{"trials":619,"activeCount":65},[],{"intervention":91,"totalTrials":104,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":634,"NA":636},{"trials":623,"activeCount":65},[],{"trials":625,"activeCount":65},[],{"trials":627,"activeCount":65},[],{"trials":629,"activeCount":65},[630],{"nctId":73,"briefTitle":74,"status":75,"phases":631,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":632,"interventions":633},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":635,"activeCount":65},[],{"trials":637,"activeCount":65},[],{"intervention":92,"totalTrials":104,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":652,"NA":654},{"trials":641,"activeCount":65},[],{"trials":643,"activeCount":65},[],{"trials":645,"activeCount":65},[],{"trials":647,"activeCount":65},[648],{"nctId":73,"briefTitle":74,"status":75,"phases":649,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":650,"interventions":651},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"trials":653,"activeCount":65},[],{"trials":655,"activeCount":65},[],{"intervention":657,"totalTrials":104,"cells":658},"Chloroquine or hydroxychloroquine",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":677,"NA":679},{"trials":660,"activeCount":65},[],{"trials":662,"activeCount":65},[],{"trials":664,"activeCount":65},[],{"trials":666,"activeCount":65},[667],{"nctId":668,"briefTitle":669,"status":355,"phases":670,"primaryCompletion":671,"completion":672,"start":673,"enrollment":65,"conditions":674,"interventions":676},"NCT04360759","Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19",[56],"2021-05-30","2021-06-30","2020-05-01",[675,18],"Covid-19",[657],{"trials":678,"activeCount":65},[],{"trials":680,"activeCount":65},[],{"intervention":682,"totalTrials":104,"cells":683},"Rifapentine",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":701,"NA":703},{"trials":685,"activeCount":65},[],{"trials":687,"activeCount":65},[],{"trials":689,"activeCount":65},[],{"trials":691,"activeCount":65},[692],{"nctId":693,"briefTitle":694,"status":304,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":700},"NCT02735590","The Correlate of Risk Targeted Intervention Study",[55,56],"2019-12-31","2016-09-20",2927,[15],[88,682],{"trials":702,"activeCount":65},[],{"trials":704,"activeCount":65},[],{"intervention":706,"totalTrials":104,"cells":707},"Prednisolone",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":727,"NA":729},{"trials":709,"activeCount":65},[],{"trials":711,"activeCount":65},[],{"trials":713,"activeCount":65},[],{"trials":715,"activeCount":65},[716],{"nctId":717,"briefTitle":718,"status":75,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT00810849","A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis",[56],"2014-02","2014-08","2008-12",1400,[35],[706,726],"Mycobacterium w immunotherapy",{"trials":728,"activeCount":65},[],{"trials":730,"activeCount":65},[],{"intervention":726,"totalTrials":104,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":745,"NA":747},{"trials":734,"activeCount":65},[],{"trials":736,"activeCount":65},[],{"trials":738,"activeCount":65},[],{"trials":740,"activeCount":65},[741],{"nctId":717,"briefTitle":718,"status":75,"phases":742,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":743,"interventions":744},[56],[35],[706,726],{"trials":746,"activeCount":65},[],{"trials":748,"activeCount":65},[],{"intervention":750,"totalTrials":104,"cells":751},"Phenobarbital",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":770,"NA":772},{"trials":753,"activeCount":65},[],{"trials":755,"activeCount":65},[],{"trials":757,"activeCount":65},[],{"trials":759,"activeCount":65},[760],{"nctId":761,"briefTitle":762,"status":75,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT03650270","Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting",[56],"2018-03-01","2015-03-01",198,[768],"Pediatric Status Epilepticus",[750],{"trials":771,"activeCount":65},[],{"trials":773,"activeCount":65},[],{"intervention":775,"totalTrials":104,"cells":776},"Hydralazine",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":798,"NA":800},{"trials":778,"activeCount":65},[],{"trials":780,"activeCount":65},[],{"trials":782,"activeCount":65},[],{"trials":784,"activeCount":65},[785],{"nctId":786,"briefTitle":787,"status":304,"phases":788,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":796},"NCT01822808","Bi Treatment With Hydralazine\u002FNitrates Versus Placebo in Africans Admitted With Acute Heart Failure",[56],"2016-01","2016-07","2013-01",500,[794,795],"Acute Heart Failure","Left Ventricular Dysfunction",[775,797],"Isosorbide Dinitrate",{"trials":799,"activeCount":65},[],{"trials":801,"activeCount":65},[],{"intervention":797,"totalTrials":104,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":816,"NA":818},{"trials":805,"activeCount":65},[],{"trials":807,"activeCount":65},[],{"trials":809,"activeCount":65},[],{"trials":811,"activeCount":65},[812],{"nctId":786,"briefTitle":787,"status":304,"phases":813,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":814,"interventions":815},[56],[794,795],[775,797],{"trials":817,"activeCount":65},[],{"trials":819,"activeCount":65},[],{"intervention":821,"totalTrials":104,"cells":822},"IV N-acetylcysteine",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":842,"NA":844},{"trials":824,"activeCount":65},[],{"trials":826,"activeCount":65},[],{"trials":828,"activeCount":65},[],{"trials":830,"activeCount":65},[831],{"nctId":832,"briefTitle":833,"status":75,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":840},"NCT02182167","A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis",[55,56],"2019-02","2014-05",102,[839],"Drug-Induced Liver Injury",[821,841],"Water",{"trials":843,"activeCount":65},[],{"trials":845,"activeCount":65},[],{"intervention":841,"totalTrials":104,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":860,"NA":862},{"trials":849,"activeCount":65},[],{"trials":851,"activeCount":65},[],{"trials":853,"activeCount":65},[],{"trials":855,"activeCount":65},[856],{"nctId":832,"briefTitle":833,"status":75,"phases":857,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":858,"interventions":859},[55,56],[839],[821,841],{"trials":861,"activeCount":65},[],{"trials":863,"activeCount":65},[],{"intervention":865,"totalTrials":33,"cells":866},"Dolutegravir 50 mg",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":868,"activeCount":65},[],{"trials":870,"activeCount":65},[],{"trials":872,"activeCount":65},[873,883],{"nctId":874,"briefTitle":875,"status":75,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":882},"NCT03991013","Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial",[55],"2022-04-26","2022-10-27","2019-08-08",192,[21],[865],{"nctId":884,"briefTitle":885,"status":75,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":892},"NCT03851588","Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis",[55],"2022-01-20","2022-06-28","2019-12-19",108,[21,15],[865],{"trials":894,"activeCount":65},[],{"trials":896,"activeCount":65},[],{"trials":898,"activeCount":65},[],{"intervention":900,"totalTrials":104,"cells":901},"BCG",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":919,"PHASE4":921,"NA":923},{"trials":903,"activeCount":65},[],{"trials":905,"activeCount":65},[],{"trials":907,"activeCount":65},[908],{"nctId":909,"briefTitle":910,"status":75,"phases":911,"primaryCompletion":912,"start":913,"enrollment":914,"conditions":915,"interventions":918},"NCT02062580","Early Versus Delayed BCG Vaccination of HIV-exposed Infants",[55],"2012-04","2010-06",149,[916,917],"HIV Exposure","HIV Infection",[900],{"trials":920,"activeCount":65},[],{"trials":922,"activeCount":65},[],{"trials":924,"activeCount":65},[],{"intervention":226,"totalTrials":104,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":937,"PHASE4":939,"NA":941},{"trials":928,"activeCount":65},[],{"trials":930,"activeCount":65},[],{"trials":932,"activeCount":65},[933],{"nctId":214,"briefTitle":215,"status":75,"phases":934,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":935,"interventions":936},[55],[222,223],[85,225,226,227,228],{"trials":938,"activeCount":65},[],{"trials":940,"activeCount":65},[],{"trials":942,"activeCount":65},[],{"intervention":227,"totalTrials":104,"cells":944},{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":946,"activeCount":65},[],{"trials":948,"activeCount":65},[],{"trials":950,"activeCount":65},[951],{"nctId":214,"briefTitle":215,"status":75,"phases":952,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":953,"interventions":954},[55],[222,223],[85,225,226,227,228],{"trials":956,"activeCount":65},[],{"trials":958,"activeCount":65},[],{"trials":960,"activeCount":65},[],{"intervention":228,"totalTrials":104,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":964,"activeCount":65},[],{"trials":966,"activeCount":65},[],{"trials":968,"activeCount":65},[969],{"nctId":214,"briefTitle":215,"status":75,"phases":970,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":971,"interventions":972},[55],[222,223],[85,225,226,227,228],{"trials":974,"activeCount":65},[],{"trials":976,"activeCount":65},[],{"trials":978,"activeCount":65},[],{"intervention":980,"totalTrials":104,"cells":981},"Rimactane",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":983,"activeCount":65},[],{"trials":985,"activeCount":65},[986],{"nctId":987,"briefTitle":988,"status":75,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":994},"NCT02953847","The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)",[54],"2017-02","2016-11",21,[15],[980,995,996],"Rifafour e-275","Rimactazid 150\u002F75",{"trials":998,"activeCount":65},[],{"trials":1000,"activeCount":65},[],{"trials":1002,"activeCount":65},[],{"trials":1004,"activeCount":65},[],{"intervention":995,"totalTrials":104,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1015,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":65},[],{"trials":1010,"activeCount":65},[1011],{"nctId":987,"briefTitle":988,"status":75,"phases":1012,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":1013,"interventions":1014},[54],[15],[980,995,996],{"trials":1016,"activeCount":65},[],{"trials":1018,"activeCount":65},[],{"trials":1020,"activeCount":65},[],{"trials":1022,"activeCount":65},[],{"intervention":996,"totalTrials":104,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":65},[],{"trials":1028,"activeCount":65},[1029],{"nctId":987,"briefTitle":988,"status":75,"phases":1030,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":1031,"interventions":1032},[54],[15],[980,995,996],{"trials":1034,"activeCount":65},[],{"trials":1036,"activeCount":65},[],{"trials":1038,"activeCount":65},[],{"trials":1040,"activeCount":65},[],{"intervention":1042,"totalTrials":104,"cells":1043},"ORM-12741",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1045,"activeCount":65},[],{"trials":1047,"activeCount":65},[1048],{"nctId":1049,"briefTitle":1050,"status":75,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT03440021","Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers",[54],"2018-12-05","2018-12-06","2018-03-26",68,[1057],"Healthy Volunteer",[1042],{"trials":1060,"activeCount":65},[],{"trials":1062,"activeCount":65},[],{"trials":1064,"activeCount":65},[],{"trials":1066,"activeCount":65},[],{"intervention":1068,"totalTrials":104,"cells":1069},"Darunavir\u002Fritonavir 800\u002F100 mg",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1071,"activeCount":65},[],{"trials":1073,"activeCount":65},[1074],{"nctId":1075,"briefTitle":1076,"status":536,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1082},"NCT03892161","Clinical Evaluation of Adjusted Doses of Darunavir\u002FRitonavir With Rifampicin in HIV-infected Volunteers",[54],"2018-11-22","2018-04-12",17,[21],[1068,1083],"Rifampicin 600mg QD tablet and DTG 50mg BD",{"trials":1085,"activeCount":65},[],{"trials":1087,"activeCount":65},[],{"trials":1089,"activeCount":65},[],{"trials":1091,"activeCount":65},[],{"intervention":1083,"totalTrials":104,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1095,"activeCount":65},[],{"trials":1097,"activeCount":65},[1098],{"nctId":1075,"briefTitle":1076,"status":536,"phases":1099,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":1080,"conditions":1100,"interventions":1101},[54],[21],[1068,1083],{"trials":1103,"activeCount":65},[],{"trials":1105,"activeCount":65},[],{"trials":1107,"activeCount":65},[],{"trials":1109,"activeCount":65},[],{"intervention":88,"totalTrials":27,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1132,"NA":1134},{"trials":1113,"activeCount":65},[],{"trials":1115,"activeCount":65},[],{"trials":1117,"activeCount":65},[],{"trials":1119,"activeCount":65},[1120,1124,1128],{"nctId":480,"briefTitle":481,"status":75,"phases":1121,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":1122,"interventions":1123},[56],[15],[88,469,488],{"nctId":73,"briefTitle":74,"status":75,"phases":1125,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":1126,"interventions":1127},[55,56],[15,82,83],[85,86,61,87,88,89,90,91,92],{"nctId":693,"briefTitle":694,"status":304,"phases":1129,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":1130,"interventions":1131},[55,56],[15],[88,682],{"trials":1133,"activeCount":65},[],{"trials":1135,"activeCount":65},[1136],{"nctId":1137,"briefTitle":1138,"status":75,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1145},"NCT00463086","Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons",[58],"2011-11","2007-11",1368,[15,1144,21],"Latent Tuberculosis Infection",[488],{"intervention":1147,"totalTrials":30,"cells":1148},"Sulfadoxine-pyrimethamine",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1150,"activeCount":65},[],{"trials":1152,"activeCount":65},[],{"trials":1154,"activeCount":65},[],{"trials":1156,"activeCount":65},[],{"trials":1158,"activeCount":65},[],{"trials":1160,"activeCount":65},[1161,1172,1179],{"nctId":1162,"briefTitle":1163,"status":75,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT00203801","Combination Antimalarials in Uncomplicated Malaria",[58],"2005-07","2002-01",700,[23],[1147,1170,1171],"Artesunate plus sulfadoxine-pyrimethamine","Artemether-lumefantrine",{"nctId":1173,"briefTitle":1174,"status":75,"phases":1175,"completion":1176,"start":484,"enrollment":126,"conditions":1177,"interventions":1178},"NCT00203736","A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria",[58],"2003-10",[23],[1147,1170],{"nctId":1180,"briefTitle":1174,"status":75,"phases":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT00203814",[58],"2005-03","2004-01",280,[23],[1147,1170],{"intervention":1170,"totalTrials":30,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1190,"activeCount":65},[],{"trials":1192,"activeCount":65},[],{"trials":1194,"activeCount":65},[],{"trials":1196,"activeCount":65},[],{"trials":1198,"activeCount":65},[],{"trials":1200,"activeCount":65},[1201,1205,1209],{"nctId":1162,"briefTitle":1163,"status":75,"phases":1202,"primaryCompletion":1165,"completion":1165,"start":1166,"enrollment":1167,"conditions":1203,"interventions":1204},[58],[23],[1147,1170,1171],{"nctId":1173,"briefTitle":1174,"status":75,"phases":1206,"completion":1176,"start":484,"enrollment":126,"conditions":1207,"interventions":1208},[58],[23],[1147,1170],{"nctId":1180,"briefTitle":1174,"status":75,"phases":1210,"completion":1182,"start":1183,"enrollment":1184,"conditions":1211,"interventions":1212},[58],[23],[1147,1170],{"intervention":1214,"totalTrials":104,"cells":1215},"Hope Soap",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1217,"activeCount":65},[],{"trials":1219,"activeCount":65},[],{"trials":1221,"activeCount":65},[],{"trials":1223,"activeCount":65},[],{"trials":1225,"activeCount":65},[],{"trials":1227,"activeCount":65},[1228],{"nctId":1229,"briefTitle":1230,"status":75,"phases":1231,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1239},"NCT03280771","The Hope Soap Study: a Hand-washing Intervention Among Children in South Africa",[58],"2014-12-15","2015-12-15","2014-09-01",288,[1237,1238],"Hand-washing Behavior","Diarrhea",[1214,1240],"Control group soap",{"intervention":1240,"totalTrials":104,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1253},{"trials":1244,"activeCount":65},[],{"trials":1246,"activeCount":65},[],{"trials":1248,"activeCount":65},[],{"trials":1250,"activeCount":65},[],{"trials":1252,"activeCount":65},[],{"trials":1254,"activeCount":65},[1255],{"nctId":1229,"briefTitle":1230,"status":75,"phases":1256,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":1235,"conditions":1257,"interventions":1258},[58],[1237,1238],[1214,1240],{"intervention":1171,"totalTrials":104,"cells":1260},{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":65},[],{"trials":1264,"activeCount":65},[],{"trials":1266,"activeCount":65},[],{"trials":1268,"activeCount":65},[],{"trials":1270,"activeCount":65},[],{"trials":1272,"activeCount":65},[1273],{"nctId":1162,"briefTitle":1163,"status":75,"phases":1274,"primaryCompletion":1165,"completion":1165,"start":1166,"enrollment":1167,"conditions":1275,"interventions":1276},[58],[23],[1147,1170,1171],{"intervention":1278,"totalTrials":104,"cells":1279},"Tetravalent Influenza Vaccine",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1281,"activeCount":65},[],{"trials":1283,"activeCount":65},[],{"trials":1285,"activeCount":65},[],{"trials":1287,"activeCount":65},[],{"trials":1289,"activeCount":65},[],{"trials":1291,"activeCount":65},[1292],{"nctId":1293,"briefTitle":1294,"status":75,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1304},"NCT06127693","Childhood Adversity, Inflammatory Reactivity and Persistent Pain",[],"2023-09-20","2022-06-21",101,[1300,1301,1302,1303],"Chronic Pain","Central Sensitisation","Immune Response","Adverse Childhood Experiences",[1278],{"intervention":1306,"totalTrials":104,"cells":1307},"Intravenous immunoglobulin",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1309,"activeCount":65},[],{"trials":1311,"activeCount":65},[],{"trials":1313,"activeCount":65},[],{"trials":1315,"activeCount":65},[],{"trials":1317,"activeCount":65},[],{"trials":1319,"activeCount":65},[1320],{"nctId":1321,"briefTitle":1322,"status":75,"phases":1323,"primaryCompletion":253,"completion":253,"start":1324,"enrollment":16,"conditions":1325,"interventions":1328},"NCT00615797","Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea",[58],"2002-05",[1326,1327],"Sydenham Chorea","Post Streptococcal Movement Disorder",[1306,1329],"standard interventions penicillin VK and haloperidol",{"intervention":1329,"totalTrials":104,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":65},[],{"trials":1335,"activeCount":65},[],{"trials":1337,"activeCount":65},[],{"trials":1339,"activeCount":65},[],{"trials":1341,"activeCount":65},[],{"trials":1343,"activeCount":65},[1344],{"nctId":1321,"briefTitle":1322,"status":75,"phases":1345,"primaryCompletion":253,"completion":253,"start":1324,"enrollment":16,"conditions":1346,"interventions":1347},[58],[1326,1327],[1306,1329],{"intervention":1349,"totalTrials":104,"cells":1350},"Amoxicillin",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1352,"activeCount":65},[],{"trials":1354,"activeCount":65},[],{"trials":1356,"activeCount":65},[],{"trials":1358,"activeCount":65},[],{"trials":1360,"activeCount":65},[],{"trials":1362,"activeCount":65},[1363],{"nctId":1364,"briefTitle":1365,"status":75,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT01253980","Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children",[58],"2011-09","2010-07",74,[1371],"Kerosene Pneumonitis",[1349],{"intervention":1374,"totalTrials":104,"cells":1375},"Salbutamol",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1377,"activeCount":65},[],{"trials":1379,"activeCount":65},[],{"trials":1381,"activeCount":65},[],{"trials":1383,"activeCount":65},[],{"trials":1385,"activeCount":65},[],{"trials":1387,"activeCount":65},[1388],{"nctId":1389,"briefTitle":1390,"status":304,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1397},"NCT00608790","Rapid Diagnosis of Pulmonary Tuberculosis",[58],"2012-12","2013-04","2008-02",600,[15],[1374,1398],"Sodium chloride 5%",{"intervention":1398,"totalTrials":104,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1402,"activeCount":65},[],{"trials":1404,"activeCount":65},[],{"trials":1406,"activeCount":65},[],{"trials":1408,"activeCount":65},[],{"trials":1410,"activeCount":65},[],{"trials":1412,"activeCount":65},[1413],{"nctId":1389,"briefTitle":1390,"status":304,"phases":1414,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1415,"interventions":1416},[58],[15],[1374,1398],{"intervention":1418,"totalTrials":104,"cells":1419},"Antihypertensive medication according to the study's algorithm",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1421,"activeCount":65},[],{"trials":1423,"activeCount":65},[],{"trials":1425,"activeCount":65},[],{"trials":1427,"activeCount":65},[],{"trials":1429,"activeCount":65},[],{"trials":1431,"activeCount":65},[1432],{"nctId":1433,"briefTitle":1434,"status":75,"phases":1435,"primaryCompletion":1436,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1444},"NCT03921086","Hypertension And Surgery Study: Evaluating the Implementation of a Hypertension Guideline Protocol",[58],"2019-03-15","2019-03-16","2019-01-14",106,[1441,1442,1443],"Hypertension","Metabolic Syndrome","Non-Compliance, Medication",[1418]]